{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:40:31Z","timestamp":1761561631486},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2012,4,17]],"date-time":"2012-04-17T00:00:00Z","timestamp":1334620800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/s11096-012-9625-3","type":"journal-article","created":{"date-parts":[[2012,4,16]],"date-time":"2012-04-16T07:59:35Z","timestamp":1334563175000},"page":"699-709","source":"Crossref","is-referenced-by-count":6,"title":["Preventable drug-related morbidity in community pharmacy: development and piloting of a complex intervention"],"prefix":"10.1007","volume":"34","author":[{"given":"Mara","family":"Pereira Guerreiro","sequence":"first","affiliation":[]},{"given":"Ana Paula","family":"Martins","sequence":"additional","affiliation":[]},{"given":"Judith Anne","family":"Cantrill","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2012,4,17]]},"reference":[{"issue":"Suppl 3","key":"9625_CR1","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1002\/(SICI)1099-1557(199710)6:3+<S79::AID-PDS294>3.3.CO;2-F","volume":"6","author":"M Goettler","year":"1997","unstructured":"Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring\u2014cost and benefit considerations. Part II: cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug Saf. 1997;6(Suppl 3):S79\u201390.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl 3","key":"9625_CR2","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1002\/(SICI)1099-1557(199710)6:3+<S71::AID-PDS282>3.3.CO;2-9","volume":"6","author":"N Muehlberger","year":"1997","unstructured":"Muehlberger N, Schneeweiss S, Hasford J. Adverse drug reaction monitoring\u2014cost and benefit considerations. Part I: frequency of adverse drug reactions causing hospital admissions. Pharmacoepidemiol Drug Saf. 1997;6(Suppl 3):S71\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"9625_CR3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1023\/A:1015570104121","volume":"24","author":"HJM Beijer","year":"2002","unstructured":"Beijer HJM, De Blaey CJ. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies. Pharm World Sci. 2002;24(2):46\u201354.","journal-title":"Pharm World Sci"},{"issue":"2","key":"9625_CR4","first-page":"77","volume":"26","author":"HP Alonso","year":"2002","unstructured":"Alonso HP, Otero Lopez MJ, Maderuelo Fernandez JA. Ingresos hospitalarios causados por medicamentos: incidencia, caracter\u00edsticas y coste [Spanish: Drug-induced hospital admissions: Incidence, characteristics and cost]. Farm Hosp. 2002;26(2):77\u201389.","journal-title":"Farm Hosp"},{"issue":"7\u20138","key":"9625_CR5","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1345\/aph.1A225","volume":"36","author":"AG Winterstein","year":"2002","unstructured":"Winterstein AG, Sauer BC, Hepler CD, Poole C. Preventable drug-related hospital admissions. Ann Pharmacother. 2002;36(7\u20138):1238\u201348.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"9625_CR6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1365-2125.2006.02698.x","volume":"63","author":"RL Howard","year":"2006","unstructured":"Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. Which drugs cause preventable hospital admissions to hospital? A systematic review. Br J Clin Pharmacol. 2006;63(2):136\u201347.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"9625_CR7","doi-asserted-by":"crossref","first-page":"365","DOI":"10.18553\/jmcp.2002.8.5.365","volume":"8","author":"NJ MacKinnon","year":"2002","unstructured":"MacKinnon NJ, Hepler CD. Preventable drug-related morbidity in older adults\u20141. Indicator development. JMCP. 2002;8(5):365\u201370.","journal-title":"JMCP"},{"issue":"2","key":"9625_CR8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.18553\/jmcp.2003.9.2.134","volume":"9","author":"NJ MacKinnon","year":"2003","unstructured":"MacKinnon NJ, Hepler CD. Preventable drug-related morbidity in older adults\u20142. Use within a managed care organisation. JMCP. 2003;9(2):134\u201341.","journal-title":"JMCP"},{"key":"9625_CR9","first-page":"29","volume":"13","author":"BC Sauer","year":"2007","unstructured":"Sauer BC, Hepler CD, Cherney B, Williamson J. Computerized Indicators of Potential Drug-related Emergency Department and Hospital Admissions. Am J Manag Care. 2007;13:29\u201335.","journal-title":"Am J Manag Care"},{"issue":"3","key":"9625_CR10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/oxfordjournals.intqhc.a002610","volume":"14","author":"CJ Morris","year":"2002","unstructured":"Morris CJ, Cantrill JA, Hepler CD, Noyce PR. Preventing drug-related morbidity\u2014determining valid indicators. Int J Qual Health Care. 2002;14(3):183\u201398.","journal-title":"Int J Qual Health Care"},{"issue":"4","key":"9625_CR11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2710.2003.00496.x","volume":"28","author":"CJ Morris","year":"2003","unstructured":"Morris CJ, Cantrill JA. Preventing drug-related morbidity\u2014the development of quality indicators. J Clin Pharm Ther. 2003;28(4):295\u2013305.","journal-title":"J Clin Pharm Ther"},{"issue":"3","key":"9625_CR12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2710.2006.00723.x","volume":"31","author":"VS Hammersley","year":"2006","unstructured":"Hammersley VS, Morris CJ, Rodgers S, Cantrill JA, Avery AJ. Applying preventable drug-related morbidity indicators to the electronic patient record in UK primary care: methodological development. J Clin Pharm Ther. 2006;31(3):223\u20139.","journal-title":"J Clin Pharm Ther"},{"key":"9625_CR13","first-page":"682","volume":"271","author":"CJ Morris","year":"2003","unstructured":"Morris CJ, Cantrill CA, Bates JR. How the use of preventable drug-related morbidity indicators can improve medicines management in primary care. Pharm J. 2003;271:682\u20136.","journal-title":"Pharm J"},{"issue":"3","key":"9625_CR14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/qshc.2003.008334","volume":"13","author":"CJ Morris","year":"2004","unstructured":"Morris CJ, Rodgers S, Hammersley VS, Avery AJ, Cantrill JA. Indicators for preventable drug related morbidity: application in primary care. Qual Saf Health Care. 2004;13(3):181\u20135.","journal-title":"Qual Saf Health Care"},{"issue":"2","key":"9625_CR15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/qshc.2005.014597","volume":"15","author":"CJ Morris","year":"2006","unstructured":"Morris CJ, Cantrill JA, Avery AJ, Howard RL. Preventing drug related morbidity: a process for facilitating changes in practice. Qual Saf Health Care. 2006;15(2):116\u201321.","journal-title":"Qual Saf Health Care"},{"issue":"10","key":"9625_CR16","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/S0149-2918(02)80063-7","volume":"24","author":"HA Robertson","year":"2002","unstructured":"Robertson HA, MacKinnon NJ. Development of a list of consensus-approved clinical indicators of preventable drug-related morbidity in older adults. Clin Ther. 2002;24(10):1595\u2013613.","journal-title":"Clin Ther"},{"issue":"1","key":"9625_CR17","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1345\/aph.1D295","volume":"38","author":"PS Flanagan","year":"2004","unstructured":"Flanagan PS, MacKinnon NJ, Bowles SK, Kirkland SA. Validation of four clinical indicators of preventable drug-related morbidity. Ann Pharmacother. 2004;38(1):20\u20134.","journal-title":"Ann Pharmacother"},{"key":"9625_CR18","first-page":"107","volume":"20","author":"MP Guerreiro","year":"2007","unstructured":"Guerreiro MP, Cantrill JA, Martins AP. Preventable drug related morbidity\u2014determining valid indicators for primary care in Portugal. Acta Med Port. 2007;20:107\u201330.","journal-title":"Acta Med Port"},{"key":"9625_CR19","doi-asserted-by":"crossref","unstructured":"Dago AM, Arcos PG, \u00c1lvarez de Toledo FS, Baena MIP, Mart\u00ednez JO, Gorostiza IO. Indicadores de riesgo de morbilidad prevenible causada por medicamentos [Spanish: Indicators of preventable drug related morbidity]. Gac Sanit. 2007; 21(1):29\u201336.","DOI":"10.1157\/13099118"},{"key":"9625_CR20","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/pds.1582","volume":"17","author":"MM Gianino","year":"2008","unstructured":"Gianino MM, Foti G, Borghese R, Lorelli S, Siliquini R, Renga G. Indicators for preventable drug-related morbidity. Practical application in home-based care. Pharmacoepidemiol Drug Saf. 2008;17:501\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"9625_CR21","volume-title":"A framework for the development and evaluation of RCTs for complex interventions to improve health","author":"Medical Research Council","year":"2000","unstructured":"Medical Research Council. A framework for the development and evaluation of RCTs for complex interventions to improve health. London: MRC; 2000."},{"key":"9625_CR22","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/bmj.321.7262.694","volume":"321","author":"M Campbell","year":"2000","unstructured":"Campbell M, Fitzpatrick R, Haynes A, Kinmonth AL, Sandercock P, Spiegelhalter D, et al. Framework for design and evaluation of complex interventions to improve health. BMJ. 2000;321:694\u20136.","journal-title":"BMJ"},{"key":"9625_CR23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1211\/ijpp.14.4.0001","volume":"14","author":"MC Watson","year":"2006","unstructured":"Watson MC. Using the Medical Research Council (UK) framework for the development and evaluation of randomised controlled trials for complex interventions to improve health [editorial]. Int J Pharm Pract. 2006;14:233\u20134.","journal-title":"Int J Pharm Pract"},{"key":"9625_CR24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1023\/B:PHAR.0000042920.34663.04","volume":"26","author":"ICK Wong","year":"2004","unstructured":"Wong ICK. Randomised controlled trials (RCTs) to evaluate complex healthcare interventions\u2014a case study. Pharm World Sci. 2004;26:247\u201352.","journal-title":"Pharm World Sci"},{"key":"9625_CR25","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1136\/bmj.320.7237.768","volume":"320","author":"J Reason","year":"2000","unstructured":"Reason J. Human error: models and management. BMJ. 2000;320:768\u201370.","journal-title":"BMJ"},{"key":"9625_CR26","doi-asserted-by":"crossref","DOI":"10.1201\/9780203010730","volume-title":"Preventing medication errors and improving drug therapy outcomes","author":"CD Hepler","year":"2003","unstructured":"Hepler CD, Segal R. Preventing medication errors and improving drug therapy outcomes. Boca Raton: CRC Press; 2003."},{"key":"9625_CR27","doi-asserted-by":"crossref","unstructured":"Beney J, Bero LA, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. Cochrane Database Syst Rev. 2000;(2). doi: 10.1002\/14651858.CD000336 .","DOI":"10.1002\/14651858.CD000336"},{"key":"9625_CR28","unstructured":"Roberts A (ed.). Business and professional facilitators. University of Sydney. Final report, 2003."},{"key":"9625_CR29","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.2042-7174.2000.tb01004.x","volume":"8","author":"MP Tully","year":"2000","unstructured":"Tully MP, Seston EM, Cantrill JA. Motivators and barriers to the implementation of pharmacist-run prescription monitoring and review services in two settings. Int J Pharm Pract. 2000;8:188\u201397.","journal-title":"Int J Pharm Pract"},{"key":"9625_CR30","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/bmj.320.7227.114","volume":"320","author":"C Pope","year":"2000","unstructured":"Pope C, Ziebland S, Mays N. Qualitative research in health care: analysing qualitative data. BMJ. 2000;320:114\u20136.","journal-title":"BMJ"},{"key":"9625_CR31","first-page":"590","volume":"26","author":"EI Paulino","year":"2010","unstructured":"Paulino EI, Guerreiro MP, Cantrill JA, Martins AP, Costa FA, Benrimoj SI. Community pharmacists\u2019 and physicians\u2019 inter-professional work\u2014insights from qualitative studies with multiple stakeholders. Rev Port Clin Geral. 2010;26:590\u2013606.","journal-title":"Rev Port Clin Geral"},{"key":"9625_CR32","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/bmj.a979","volume":"337","author":"P Craig","year":"2008","unstructured":"Craig P, Dieppe P, Macintyre S, Mitchie S, Nazareth I, Petticrew M. Developing and evaluating complex interventions: the new Medical Research Council guidance. BMJ. 2008;337:979\u201383.","journal-title":"BMJ"},{"key":"9625_CR33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/pds.711","volume":"11","author":"AP Martins","year":"2002","unstructured":"Martins AP, Miranda AC, Mendes Z, Soares MA, Ferreira P, Nogueira A. Self-medication in a Portuguese urban population: a prevalence study. Pharmacoepidemiol Drug Saf. 2002;11:409\u201314.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"9625_CR34","first-page":"600","volume":"53","author":"CM Hughes","year":"2003","unstructured":"Hughes CM, McCann S. Perceived interprofessional barriers between community pharmacists and general practitioners: a qualitative assessment. Br J Gen Pract. 2003;53:600\u20136.","journal-title":"Br J Gen Pract"},{"key":"9625_CR35","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.2042-7174.1999.tb00962.x","volume":"7","author":"RN Reebye","year":"1999","unstructured":"Reebye RN, Avery A, Van Den Bosch WJHM, Aslam M, Nijholt A, Van Der Bij A. Exploring community pharmacists\u2019 perceptions of their professional relationships with physicians, in Canada and The Netherlands. Int J Pharm Pract. 1999;7:158.","journal-title":"Int J Pharm Pract"},{"key":"9625_CR36","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0277-9536(00)00393-2","volume":"53","author":"J Edmunds","year":"2001","unstructured":"Edmunds J, Calnan MW. The reprofessionalisation of community pharmacy? An exploration of attitudes to extended roles for community pharmacists amongst pharmacists and general practitioners in the United Kingdom. Soc Sci Med. 2001;53:943\u201355.","journal-title":"Soc Sci Med"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-012-9625-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-012-9625-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-012-9625-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T01:54:36Z","timestamp":1559354076000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-012-9625-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,17]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["9625"],"URL":"https:\/\/doi.org\/10.1007\/s11096-012-9625-3","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"value":"2210-7703","type":"print"},{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,17]]}}}